Pregnancy outcomes after early fetal exposure to dimethyl fumarate, glatiramer acetate or natalizumab

Researchers from the Danish Multiple Sclerosis Registry have published an analysis of adverse pregnancy outcomes among women with MS treated with injectable first-line treatments (dimethyl fumarate, glatiramer acetate or natalizumab). More information can be found here.